CD38: A Potential Therapeutic Target in Cardiovascular Disease
- 29 May 2020
- journal article
- review article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 35 (4) , 815-828
Abstract
Substantial research has demonstrated the association between cardiovascular disease and the dysregulation of intracellular calcium, ageing, reduction in nicotinamide adenine dinucleotide NAD+ content, and decrease in sirtuin activity. CD38, which comprises the soluble type, type II, and type III, is the main NADase in mammals. This molecule catalyses the production of cyclic adenosine diphosphate ribose (cADPR), nicotinic acid adenine dinucleotide phosphate (NAADP), and adenosine diphosphate ribose (ADPR), which stimulate the release of Ca2+, accompanied by NAD+ consumption and decreased sirtuin activity. Therefore, the relationship between cardiovascular disease and CD38 has been attracting increased attention. In this review, we summarize the structure, regulation, function, targeted drug development, and current research on CD38 in the cardiac context. More importantly, we provide original views about the as yet elusive mechanisms of CD38 action in certain cardiovascular disease models. Based on our review, we predict that CD38 may serve as a novel therapeutic target in cardiovascular disease in the future.Keywords
Funding Information
- National Natural Science Foundation of China (No. 81770337)
- Hunan Provincial Natural Science Youth Foundation of China (No. 2019JJ50881)
- Hunan Provincial Clinical Medical Technology Innovation Guide Project (No. 2018SK50413)
This publication has 146 references indexed in Scilit:
- The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db/db miceCardiovascular Diabetology, 2012
- CD38 and chronic lymphocytic leukemia: a decade laterBlood, 2011
- CD38 Exacerbates Focal Cytokine Production, Postischemic Inflammation and Brain Injury after Focal Cerebral IschemiaPLOS ONE, 2011
- Ablation of triadin causes loss of cardiac Ca 2+ release units, impaired excitation–contraction coupling, and cardiac arrhythmiasProceedings of the National Academy of Sciences, 2009
- Regulation of the cd38 promoter in human airway smooth muscle cells by TNF-α and dexamethasoneRespiratory Research, 2008
- Endogenous ADP-ribose enables calcium-regulated cation currents through TRPM2 channels in neutrophil granulocytesBiochemical Journal, 2006
- Regulation of intracellular levels of NAD: A novel role for CD38Biochemical and Biophysical Research Communications, 2006
- Structure and functional regulation of the CD38 promoterBiochemical and Biophysical Research Communications, 2006
- Human CD38: a glycoprotein in search of a functionImmunology Today, 1994
- A Single Protein Immunologically Identified as CD38 Displays NAD+ Glycohydrolase, ADP-Ribosyl Cyclase and Cyclic ADP-Ribose Hydrolase Activities at the Outer Surface of Human ErythrocytesBiochemical and Biophysical Research Communications, 1993